Journal of Oncology / 2020 / Article / Tab 4

Research Article

Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece

Table 4

Response to first-line treatment according to the chemotherapy regimen.

ResponseFirst-line chemotherapy regimenTotal
Nab-paclitaxel-gemcitabineFOLFIRINOX/CAPOXIRIGemcitabineOthers

CRN (%)51006
5.52.60.00.03.8
PRN (%)39121456
42.931.610.022.235.7
SDN (%)281331054
30.834.230.055.634.4
PDN (%)19126441
20.931.660.022.226.1
TotalN (%)91381018157
58.024.26.411.4100.0

CAPOXIRI, oxaliplatin/irinotecan/capecitabine; CR, complete response; FOLFIRINOX, oxaliplatin/irinotecan/leucovorin/5-fluorouracil; PD, progressive disease; PR, partial response; SD, stable disease.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.